Navigation Links
Genomma Lab Internacional Acquires UNIGASTROZOL
Date:7/29/2008

MEXICO CITY, July 29 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company"), a leading Mexican over-the-counter pharmaceuticals and personal care products company announced yesterday that it had acquired the brand and related rights and registrations of UNIGASTROZOL, from Unipharm de Mexico, S.A. de C.V. This over-the-counter product is used for the reduction and control of gastrointestinal symptoms that are produced by excessive acid secretion and is also helpful in the treatment of gastritis, heartburn, reflux and esophagitis. It is based on a molecule that allows for faster absorption than that of Omeoprazol.

With this acquisition, Genomma Lab complements its line of anti-acid products, in particular its product Genoprazol. The category under which Unigastrozol participates reached sales of over US$ 50 million in 2007.

This is Genomma's first acquisition since listing on the Mexican Stock Exchange in June, when it raised capital seeking to accelerate growth.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico and has a growing international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has significantly grown its revenue and profitability through a combination of a successful new product development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB".

Web Site: http://www.genommalab.com

Contact in Mexico City: Kristi King Etchberger, CFO; kking@genommalab.com; Tel. (55) 5081 0000

Contacts in NY: Maria Barona/Kenia Vargas; mbarona@i-advize.com; Tel. 212 406 3691/3695


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
4. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
5. Food Bank For New York City Acquires FoodChange
6. Concentra Acquires Assets of Renew Health & Wellness
7. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
8. NNN Healthcare/Office REIT Acquires St. Mary Physicians Center in Long Beach, California
9. NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania
10. Hologic Acquires Biolucent, Inc.
11. Radiation Therapy Services Acquires North Carolina Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the ... CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. ... across the United States. , “There are currently no approved drugs that address ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... , February 23, 2017 Tillotts ... the Berlin office was opened ... Kritikos . The portfolio includes Entocort ® for ... the treatment of ulcerative colitis, and VistaPrep ® ... the Swiss specialty pharmaceutical company focused on the treatment ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: